1/7/2013

Rhythm Pharmaceuticals said it is beginning a midstage trial to assess the safety and efficacy of its experimental drug RM-493 on weight reduction, as well as its effect on glucose and insulin resistance in obese patients. RM-493 is a melanocortin 4 receptor agonist.

Related Summaries